Martin Welschof, BioInvent CEO
June 16, 2022 08:48 AM EDTUpdated 10:47 AM
Deals

Ex­elix­is taps in­to can­cer an­ti­body dis­cov­er­er out of Swe­den

Kyle LaHucik

Senior Reporter

Ex­elix­is is dol­ing out $25 mil­lion to snag rights to choose three tar­gets found by BioIn­vent.

The Cal­i­for­nia can­cer drug­mak­er is link­ing arms with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times